Fernandez Kamilah, Cheung Laraine H, Balasinkam Sabesan, Taddesse-Heath Lekidelu
Pathology and Laboratory Medicine, Howard University Hospital, Washington, D.C., USA.
Pathology and Laboratory Medicine, Howard University College of Medicine, Washington, D.C., USA.
Cureus. 2023 Feb 27;15(2):e35541. doi: 10.7759/cureus.35541. eCollection 2023 Feb.
Splenic marginal zone lymphoma (SMZL) is an uncommon low-grade B-cell lymphoma. It is an indolent lymphoma with a median survival rate of greater than 10 years. Most patients are asymptomatic, but some patients may present with upper abdominal pain and distention, while others may present with splenomegaly, emaciation, fatigue, or weight loss. Due to the long median survival, patients with SMZL may develop a second primary malignancy. Pancreatic adenocarcinoma is the most common malignant neoplasm of the pancreas. It has a poor prognosis with a five-year survival rate of 10%. Fifty percent of patients have metastatic disease on presentation. However, the spleen is not a common site of metastasis for malignant tumors from other primary sites including the pancreas. Here we present a case of a 78-year-old African American patient, who was found to have previously undiagnosed, concurrent metastatic pancreatic adenocarcinoma and SMZL diagnosed on splenectomy for a suspected splenic abscess.
脾边缘区淋巴瘤（SMZL）是一种罕见的低度B细胞淋巴瘤。它是一种惰性淋巴瘤，中位生存期超过10年。大多数患者无症状，但有些患者可能出现上腹部疼痛和腹胀，而另一些患者可能出现脾肿大、消瘦、疲劳或体重减轻。由于中位生存期长，SMZL患者可能会发生第二种原发性恶性肿瘤。胰腺腺癌是胰腺最常见的恶性肿瘤。其预后较差，五年生存率为10%。50%的患者在就诊时已有转移性疾病。然而，脾脏并非包括胰腺在内的其他原发部位恶性肿瘤常见的转移部位。在此，我们报告一例78岁非裔美国患者，该患者因疑似脾脓肿行脾切除术，术后被发现同时患有先前未诊断出的转移性胰腺腺癌和SMZL。
